Net Income

Klotho Neurosciences will present its novel gene therapy for Alzheimer's and ALS at a key summit, seeking to turn scientific promise into clinical reality.

A new partnership aims to bring cutting-edge cancer trials to community clinics, accelerating drug development and expanding patient access to care.

The Spanish epigenetics leader will showcase its advanced CNS and oncology pipeline at key January conferences, seeking partners and investor validation.

Collegium Pharmaceutical projects robust 2026 revenue fueled by its ADHD drug Jornay PM, savvy debt refinancing, and a proactive generic strategy.

Quantum PKI appoints Dr. Judy Gounden as CEO, signaling a strategic push for global growth, crypto-agility, and diverse leadership in digital trust.

The opioid treatment specialist projects over $1.1B in revenue, driven by its flagship drug SUBLOCADE and a major strategic overhaul in the U.S.

Cybersecurity firm Corero appoints an award-winning leader to supercharge its partner program, signaling a major push in the competitive DDoS defense market.

With gold hitting record highs, investors are keenly awaiting Kinross's update on three critical US projects that could define its production for a decade.

Calgary-based Horizon Petroleum faces a Management Cease Trade Order over delayed financial filings, raising questions about its European operations.

Challenger brand Kodiak partners with analytics giant NIQ, signaling a new data-driven era for competition in the crowded CPG breakfast and snacking aisles.

Luxury brand owner Tapestry partners with Pivot Energy on Illinois solar projects, powering homes and funding new green job training programs for locals.

Westwater Resources heads to a key investor conference, carrying the weight of its Alabama graphite projects and the future of America's EV supply chain.

Amid market headwinds, JD.com cancels $3B in shares to boost value, signaling deep confidence while juggling costly strategic growth initiatives.

A major customer delay impacts Ceragon's Q4 revenue, but the company projects significant growth in 2026, banking on a strong backlog and new markets.

How a blend of private capital and pragmatic regulation is turning Singapore into a global hub for longevity research, pushing scientific and ethical boundaries.

As the eVTOL race intensifies, Vertical Aerospace appoints key execs from Lotus, Nike, and AB InBev to spearhead its push for certification and scale.

Oculis is advancing a neuroprotective drug for optic neuropathies and a first-of-its-kind eye drop for diabetic macular edema, aiming at $10B+ markets.

Azafaros presents its promising drug, nizubaglustat, for untreatable rare neurological disorders, backed by major funding and late-stage clinical trials.

At CES 2026, new optical engines from Appotronics promise to make AR glasses as light as normal eyewear, sparking a race toward an affordable, all-day wearable future.

South Korean gim specialist Daingt is leveraging proprietary data and a 20-year legacy to innovate its seaweed, aiming to dominate the booming global market.